Risk factors for venous thromboembolism.

Venous thromboembolism is a common and potentially lethal disease. Patients who have pulmonary embolism are at especially high risk for death. Death owing to pulmonary embolism is independent of other comorbid conditions (e.g., cancer, chronic heart disease, or lung disease). Sudden death is often the first clinical manifestation. Only a reduction in the incidence of venous thromboembolism can reduce sudden death owing to pulmonary embolism and venous stasis syndrome owing to deep vein thrombosis. The incidence of venous thromboembolism has been relatively constant since about 1980. Improvement in the incidence of venous thromboembolism will require better recognition of persons at risk, improved estimates of the magnitude of risk, the avoidance of risk exposure when possible, more widespread use of safe and effective prophylaxis when risk is unavoidable, and targeting of prophylaxis to those persons who will benefit most. Recognition of venous thromboembolism as a multifactorial disease with genetic and genetic-environmental interaction has provided significant insights into its epidemiology and offers the possibility of improved identification of persons at risk for incident and recurrent venous thromboembolism.

[1]  A. Kierkegaard Incidence of acute deep vein thrombosis in two districts. A phlebographic study. , 1980, Acta chirurgica Scandinavica.

[2]  S Hulley,et al.  Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. , 1998, JAMA.

[3]  M. Stampfer,et al.  Epidemiology of Oral Contraceptives and Cardiovascular Disease , 1998, Annals of Internal Medicine.

[4]  R. M. Vazquez,et al.  Thromboembolic complications associated with L‐asparaginase therapy. Etiologic role of low antithrombin III and plasminogen levels and therapeutic correction by fresh frozen plasma , 1985, Cancer.

[5]  G. Bannister,et al.  Death and thromboembolic disease after total hip replacement. A series of 1162 cases with no routine chemical prophylaxis. , 1995, The Journal of bone and joint surgery. British volume.

[6]  B. Dahlbäck,et al.  Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. , 1995, Blood.

[7]  J. T. ten Cate,et al.  ACQUIRED RISK FACTORS AND DEEP VEIN THROMBOSIS IN SYMPTOMATIC OUT PATIENTS , 1994, Thrombosis and Haemostasis.

[8]  D. Mant,et al.  Oral contraceptives and venous thromboembolism: findings in a large prospective study. , 1986, British medical journal.

[9]  H. Büller,et al.  Deficiencies of coagulation-inhibiting and fibrinolytic proteins in outpatients with deep-vein thrombosis. , 1990, The New England journal of medicine.

[10]  F. Grodstein,et al.  Postmenopausal Hormone Use and Secondary Prevention of Coronary Events in the Nurses' Health Study: A Prospective, Observational Study , 2001, Annals of Internal Medicine.

[11]  F. Lundin,et al.  Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. , 1991, American journal of epidemiology.

[12]  E. Vittinghoff,et al.  Postmenopausal Hormone Therapy Increases Risk for Venous Thromboembolic Disease: The Heart and Estrogen/progestin Replacement Study , 2000, Annals of Internal Medicine.

[13]  P. Ridker,et al.  Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. , 1995, The New England journal of medicine.

[14]  H. Jick,et al.  Risk of venous thromboembolism among users of third generation oral contraceptives compared with users of oral contraceptives with levonorgestrel before and after 1995: cohort and case-control analysis , 2000, BMJ : British Medical Journal.

[15]  M. Samama,et al.  An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. , 2000, Archives of internal medicine.

[16]  P. Meraj,et al.  Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile. , 1999, Journal of the American College of Cardiology.

[17]  N Rifai,et al.  Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.

[18]  J. Vandenbroucke,et al.  Risk of venous thrombosis with use of current low-dose oral contraceptives is not explained by diagnostic suspicion and referral bias. , 1999, Archives of internal medicine.

[19]  R J Hettiarachchi,et al.  Undiagnosed malignancy in patients with deep vein thrombosis , 1998, Cancer.

[20]  A. Kierkegaard Incidence and Diagnosis of Deep Vein Thrombosis Associated with Pregnancy , 1983, Acta obstetricia et gynecologica Scandinavica.

[21]  W. Coon,et al.  Some epidemiologic considerations of thromboembolism. , 1959, Surgery, gynecology & obstetrics.

[22]  C. Furberg,et al.  Venous thromboembolic events associated with hormone replacement therapy. , 1997, JAMA.

[23]  C. Warlow,et al.  Deep venous thrombosis of the legs after strokes. Part I--incidence and predisposing factors. , 1976, British medical journal.

[24]  F. Lederle Heparin Prophylaxis for Medical Patients? , 1998, Annals of Internal Medicine.

[25]  L. García-Rodríguez,et al.  Hormone replacement therapy and the risk of hospitalization for venous thromboembolism: a population-based study in southern Europe. , 1998, American journal of epidemiology.

[26]  Pieter H. Reitsma,et al.  Mutation in blood coagulation factor V associated with resistance to activated protein C , 1994, Nature.

[27]  D. Hosmer,et al.  Physician practices in the prevention of venous thromboembolism. , 1991, Annals of internal medicine.

[28]  O. Böstman,et al.  Deep venous thrombosis and pulmonary embolism in patients with acute spinal cord injury: a comparison with nonparalyzed patients immobilized due to spinal fractures. , 1985, The Journal of trauma.

[29]  P. Reitsma,et al.  Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. , 1994 .

[30]  J. Hirsh,et al.  The thrombogenic effect of anticancer drug therapy in women with stage II breast cancer. , 1988, The New England journal of medicine.

[31]  N. Gibbs,et al.  Venous thrombosis of the lower limbs with particular reference to bed‐rest , 1957, The British journal of surgery.

[32]  L. Melton,et al.  Incidence of venous thromboembolism in hospitalized patients vs community residents. , 2001, Mayo Clinic proceedings.

[33]  P. Reitsma,et al.  Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation , 1994, The Lancet.

[34]  Diederick E Grobbee,et al.  Third generation oral contraceptives and risk of venous thrombosis: meta-analysis , 2001, BMJ : British Medical Journal.

[35]  H. Saito,et al.  Increased incidence of thromboembolism in stage IV breast cancer patients treated with a five‐drug chemotherapy regimen , 1984, Cancer.

[36]  T. Kjellstrom,et al.  Deep venous thrombosis and occult malignancy: an epidemiological study , 1994, BMJ.

[37]  J. Vandenbroucke,et al.  Gene-gene and gene-environment interactions determine risk of thrombosis in families with inherited antithrombin deficiency. , 1999, Blood.

[38]  D. Hosmer,et al.  A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. , 1991, Archives of internal medicine.

[39]  D. Bergqvist,et al.  Cost of Long-Term Complications of Deep Venous Thrombosis of the Lower Extremities: An Analysis of a Defined Patient Population in Sweden , 1997, Annals of Internal Medicine.

[40]  José A Fernández,et al.  Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. , 2001, Blood.

[41]  I. Pinder,et al.  The incidence of fatal pulmonary embolism after knee replacement with no prophylactic anticoagulation. , 1993, The Journal of bone and joint surgery. British volume.

[42]  A. Laupacis,et al.  Use of statins and the subsequent development of deep vein thrombosis. , 2001, Archives of internal medicine.

[43]  J. Carson,et al.  Risk of venous thromboembolism in users of hormone replacement therapy , 1996, The Lancet.

[44]  R. Bick Coagulation Abnormalities in Malignancy: A Review , 1992, Seminars in thrombosis and hemostasis.

[45]  J. Manson,et al.  A prospective study of risk factors for pulmonary embolism in women. , 1997, JAMA.

[46]  B. Dahlbäck,et al.  Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[47]  E. Bromfield,et al.  Relative Risk of Deep Venous Thrombosis or Pulmonary Embolism Post-Stroke Based on Ambulatory Status , 1988 .

[48]  L. Libow,et al.  Autopsy study of the elderly institutionalized patient. Review of 234 autopsies. , 1988, Archives of internal medicine.

[49]  M. Prins,et al.  Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. , 1992, The New England journal of medicine.

[50]  Jean-Yves Lefrant,et al.  Complications of Femoral and Subclavian Venous Catheterization in Critically Ill Patients: A Randomized Controlled Trial , 2001 .

[51]  J. Olsen,et al.  The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. , 1998, The New England journal of medicine.

[52]  B. Lindblad,et al.  A prospective study of the incidence of deep‐vein thrombosis within a defined urban population , 1992, Journal of internal medicine.

[53]  R. Tait,et al.  Risk Factors for Pregnancy Associated Venous Thromboembolism , 1997, Thrombosis and Haemostasis.

[54]  W M O'Fallon,et al.  Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. , 1998, Archives of internal medicine.

[55]  Deborah Grady,et al.  Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II). , 2002, JAMA.

[56]  A prospective investigation of pulmonary embolism in women and men. , 1992, JAMA.

[57]  F R Rosendaal,et al.  Risk Factors for Venous Thrombotic Disease , 1999, Thrombosis and Haemostasis.

[58]  G. Raskob,et al.  Underuse of venous thromboembolism prophylaxis for general surgery patients: physician practices in the community hospital setting. , 1998, Archives of internal medicine.

[59]  P. Romano,et al.  Predictors of rehospitalization for symptomatic venous thromboembolism after total hip arthroplasty. , 2000, The New England journal of medicine.

[60]  G. Eklund,et al.  ORAL CONTRACEPTIVES AND THROMBOEMBOLIC DISEASE: EFFECTS OF LOWERING ŒSTROGEN CONTENT , 1980, The Lancet.

[61]  B. Barlogie,et al.  Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. , 2001, Blood.

[62]  W. Kannel,et al.  Risk factors for pulmonary embolism: The Framingham study , 1983 .

[63]  F. Rosendaal,et al.  Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study , 1993, The Lancet.

[64]  J. Vandenbroucke,et al.  Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen , 1995, The Lancet.

[65]  W M O'Fallon,et al.  Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. , 2000, Archives of internal medicine.

[66]  J. Szalai,et al.  A prospective study of venous thromboembolism after major trauma. , 1994, The New England journal of medicine.

[67]  R. Madhok,et al.  Trends in the utilization of primary total hip arthroplasty, 1969 through 1990: a population-based study in Olmsted County, Minnesota. , 1993, Mayo Clinic proceedings.

[68]  H. Ory,et al.  Estrogen and progestin components of oral contraceptives: relationship to vascular disease. , 1997, Contraception.

[69]  K. Newton,et al.  Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens , 1996, The Lancet.

[70]  H. Liebman,et al.  Depression of functional and antigenic plasma antithrombin III (AT‐III) due to therapy with L‐asparaginase , 1982, Cancer.

[71]  M. Prins,et al.  A Prospective Study of Asymptomatic Carriers of the Factor V Leiden Mutation To Determine the Incidence of Venous Thromboembolism , 2001, Annals of Internal Medicine.

[72]  P. Reitsma,et al.  High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance) , 1995, Blood.

[73]  A. Zwinderman,et al.  Thromboembolic events during chemotherapy for germ cell cancer: a cohort study and review of the literature. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  L. Melton,et al.  Predictors of recurrence after deep vein thrombosis and pulmonary embolism: a population-based cohort study. , 2000, Archives of internal medicine.

[75]  S. Schulman,et al.  Incidence of cancer after prophylaxis with warfarin against recurrent venous thromboembolism. Duration of Anticoagulation Trial. , 2000, The New England journal of medicine.

[76]  T. Lindahl,et al.  APC-resistance Is a Risk Factor for Postoperative Thromboembolism in Elective Replacement of the Hip or Knee – A Prospective Study , 1999, Thrombosis and Haemostasis.

[77]  P. Monagle,et al.  Central venous catheter related thrombosis in children: analysis of the Canadian Registry of Venous Thromboembolic Complications. , 1998, The Journal of pediatrics.

[78]  J. Keller,et al.  Venous Thromboembolism and Other Venous Disease in the Tecumseh Community Health Study , 1973, Circulation.

[79]  P. Ridker,et al.  Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. , 1995, Circulation.

[80]  B Urquhart,et al.  Effects of epidural anesthesia on the incidence of deep-vein thrombosis after total knee arthroplasty. , 1991, The Journal of bone and joint surgery. American volume.

[81]  Paolo Prandoni,et al.  The Long-Term Clinical Course of Acute Deep Venous Thrombosis , 1996, Annals of Internal Medicine.

[82]  World Health Organization Collaborative Study of Cardiov Contarception Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study , 1995, The Lancet.

[83]  J. Martin,et al.  Autopsy Proven Pulmonary Embolism in Hospital Patients: Are We Detecting Enough Deep Vein Thrombosis? , 1989, Journal of the Royal Society of Medicine.

[84]  W. Coon Risk factors in pulmonary embolism. , 1976, Surgery, gynecology & obstetrics.

[85]  B. Yawn,et al.  Risk factors for deep vein thrombosis and pulmonary embolism during pregnancy or post partum: a population-based, case-control study. , 2001, American journal of obstetrics and gynecology.

[86]  W. Spitzer,et al.  Third generation oral contraceptives and risk of venous thromboembolic disorders: an international case-control study , 1996, BMJ.

[87]  L. Melton,et al.  Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study. , 2002, Archives of internal medicine.

[88]  H. Jick,et al.  Tamoxifen and risk of idiopathic venous thromboembolism. , 1998, British journal of clinical pharmacology.